相似文献
1
Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents.
Bioorg Med Chem. 2010 Mar 1;18(5):1899-909. doi: 10.1016/j.bmc.2010.01.037. Epub 2010 Jan 25.
2
Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.
J Med Chem. 2005 Dec 1;48(24):7733-49. doi: 10.1021/jm050758z.
3
Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.
J Med Chem. 2008 Jun 12;51(11):3104-15. doi: 10.1021/jm701066a. Epub 2008 May 6.
4
Synthesis and evaluation of antitumor activity of novel N-acyllavendamycin analogues and quinoline-5,8-diones.
Bioorg Med Chem. 2007 Jan 1;15(1):495-510. doi: 10.1016/j.bmc.2006.09.039. Epub 2006 Oct 10.
5
Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
Bioorg Med Chem. 2004 Apr 1;12(7):1667-87. doi: 10.1016/j.bmc.2004.01.021.
6
Novel lavendamycin analogues as potent HIV-reverse transcriptase inhibitors: synthesis and evaluation of anti-reverse transcriptase activity of amide and ester analogues of lavendamycin.
J Med Chem. 2003 Dec 18;46(26):5773-80. doi: 10.1021/jm0304414.
7
Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
J Med Chem. 1998 Nov 19;41(24):4755-66. doi: 10.1021/jm980328r.
8
Synthesis of new quinolinequinone derivatives and preliminary exploration of their cytotoxic properties.
J Med Chem. 2013 May 23;56(10):3806-19. doi: 10.1021/jm301689x. Epub 2013 May 1.
9
3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.
Biochem Pharmacol. 2003 Oct 1;66(7):1199-206. doi: 10.1016/s0006-2952(03)00452-0.
10
Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1.
Bioorg Med Chem Lett. 1998 Mar 3;8(5):545-8. doi: 10.1016/s0960-894x(98)00069-9.
引用本文的文献
1
Discovery of Sphingosine Kinase Inhibition by Modified Quinoline-5,8-Diones.
Pharmaceuticals (Basel). 2025 Feb 18;18(2):268. doi: 10.3390/ph18020268.
2
Exploring the Therapeutic Marvels: A Comprehensive Review on the Biological Potential of Quinoline-5,8-Dione.
Med Chem. 2024;20(4):385-396. doi: 10.2174/0115734064287677231215070816.
3
Biological activities of polypyridyl-type ligands: implications for bioinorganic chemistry and light-activated metal complexes.
Curr Opin Chem Biol. 2021 Apr;61:191-202. doi: 10.1016/j.cbpa.2021.01.016. Epub 2021 Mar 30.
4
5,8-Quinolinedione Scaffold as a Promising Moiety of Bioactive Agents.
Molecules. 2019 Nov 14;24(22):4115. doi: 10.3390/molecules24224115.
5
Intramolecular hydrogen bonding, π-π stacking interactions, and substituent effects of 8-hydroxyquinoline derivative supermolecular structures: a theoretical study.
J Mol Model. 2019 Jul 23;25(8):241. doi: 10.1007/s00894-019-4140-2.
6
Development of novel amino-quinoline-5,8-dione derivatives as NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities.
Eur J Med Chem. 2018 Jun 25;154:199-209. doi: 10.1016/j.ejmech.2018.05.025. Epub 2018 May 18.
7
Synthesis, Structure and Cytotoxic Activity of Mono- and Dialkoxy Derivatives of 5,8-Quinolinedione.
Molecules. 2016 Jan 27;21(2):156. doi: 10.3390/molecules21020156.
8
Synthesis of 8-hydroxyquinoline derivatives as novel antitumor agents.
ACS Med Chem Lett. 2012 Dec 20;4(2):170-4. doi: 10.1021/ml300238z. eCollection 2013 Feb 14.
9
Synthesis of new quinolinequinone derivatives and preliminary exploration of their cytotoxic properties.
J Med Chem. 2013 May 23;56(10):3806-19. doi: 10.1021/jm301689x. Epub 2013 May 1.
10
Synthesis and characterization of novel unsymmetrical and symmetrical 3-halo- or 3-methoxy-substituted 2-dibenzoylamino-1,4-naphthoquinone derivatives.
Molecules. 2013 Feb 4;18(2):1973-84. doi: 10.3390/molecules18021973.
本文引用的文献
1
Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.
J Med Chem. 2008 Jun 12;51(11):3104-15. doi: 10.1021/jm701066a. Epub 2008 May 6.
2
Synthesis and evaluation of antitumor activity of novel N-acyllavendamycin analogues and quinoline-5,8-diones.
Bioorg Med Chem. 2007 Jan 1;15(1):495-510. doi: 10.1016/j.bmc.2006.09.039. Epub 2006 Oct 10.
3
Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.
J Med Chem. 2005 Dec 1;48(24):7733-49. doi: 10.1021/jm050758z.
4
DT-diaphorase: a target for new anticancer drugs.
Cancer Treat Rev. 2004 Aug;30(5):437-49. doi: 10.1016/j.ctrv.2004.01.002.
5
Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates.
Methods Enzymol. 2004;382:355-64. doi: 10.1016/S0076-6879(04)82019-6.
6
Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
Bioorg Med Chem. 2004 Apr 1;12(7):1667-87. doi: 10.1016/j.bmc.2004.01.021.
7
Novel lavendamycin analogues as potent HIV-reverse transcriptase inhibitors: synthesis and evaluation of anti-reverse transcriptase activity of amide and ester analogues of lavendamycin.
J Med Chem. 2003 Dec 18;46(26):5773-80. doi: 10.1021/jm0304414.
8
Preliminary observations on the use of streptonigrin as an antitumor agent in human beings.
Antibiot Chemother (Northfield). 1961 Mar;11:147-50.
9
Clinical observations on the effects of streptonigrin in patients with neoplastic disease.
Antibiot Chemother (Northfield). 1961 Mar;11:178-83.
10
Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin.
Mol Cancer Ther. 2003 Jun;2(6):517-26.
Zotero 插件